RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+9.98%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.37B
AUM Growth
+$1.37B
(+28%)
Cap. Flow
+$229M
Cap. Flow
% of AUM
16.71%
Top 10 Holdings %
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13
Top Buys
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$28.6M |
| 2 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$16.6M |
| 3 |
ADPT
Adeptus Health Inc.
ADPT
|
$14.2M |
| 4 |
Collegium Pharmaceutical
COLL
|
$13.5M |
| 5 |
Acadia Healthcare
ACHC
|
$11.7M |
Top Sells
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
$22.5M |
| 2 |
SRCL
Stericycle Inc
SRCL
|
$10.3M |
| 3 |
Labcorp
LH
|
$9.46M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$8.16M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$7.98M |
Sector Composition
| 1 | Healthcare | 76.77% |
| 2 | Financials | 1.46% |
| 3 | Technology | 0.96% |
| 4 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$372B
| $50.2M | 3.66% | 746,423 +146,423 | +24% | +$9.84M |
|
2
Medtronic
MDT
$119B
| $42.2M | 3.08% | 570,000 -2,300 | -0.4% | -$170K |
|
3
Bausch Health
BHC
$2.74B
| $42M | 3.07% | 189,250 +34,250 | +22% | +$7.61M |
|
|
4
Acadia Healthcare
ACHC
$2.12B
| $40.1M | 2.93% | 511,750 +149,250 | +41% | +$11.7M |
|
5
HCA Healthcare
HCA
$94.5B
| $38.3M | 2.8% | 422,500 | – | – |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $36.9M | 2.69% | 121,500 +9,000 | +8% | +$2.73M |
|
7
McKesson
MCK
$85.4B
| $33.6M | 2.45% | 149,500 +500 | +0.3% | +$112K |
|
|
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $30.6M | 2.24% | 508,059 +474,953 | +1,435% | +$28.6M |
|
9
Gilead Sciences
GILD
$140B
| $30.1M | 2.2% | 257,500 +2,500 | +1% | +$293K |
|
|
RDUS
10
DELISTED
Radius Health, Inc.
RDUS
| $29M | 2.12% | 429,000 +29,000 | +7% | +$1.96M |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $27.9M | 2.04% | 154,500 +46,250 | +43% | +$8.36M |
|
12
Pfizer
PFE
$141B
| $25.5M | 1.86% | 760,000 | – | – |
|
13
Humana
HUM
$36.5B
| $25.2M | 1.84% | 131,500 +24,000 | +22% | +$4.59M |
|
14
Amgen
AMGN
$155B
| $23.9M | 1.75% | 156,000 -8,000 | -5% | -$1.23M |
|
|
THOR
15
DELISTED
THORATEC CORPORATION
THOR
| $23.7M | 1.73% | 532,500 +17,500 | +3% | +$780K |
|
|
CELG
16
DELISTED
Celgene Corp
CELG
| $22.9M | 1.67% | 198,000 +3,500 | +2% | +$405K |
|
|
EVHC
17
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $22.5M | 1.64% | 570,000 | – | – |
|
18
Travere Therapeutics
TVTX
$1.56B
| $22.4M | 1.63% | 675,000 -25,000 | -4% | -$829K |
|
|
TMH
19
DELISTED
Team Health Holdings Inc
TMH
| $20.4M | 1.49% | 312,500 +1,500 | +0.5% | +$98K |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $19.9M | 1.46% | 156,500 | – | – |
|
21
Cigna
CI
$80.3B
| $19.8M | 1.44% | 122,000 | – | – |
|
22
Eli Lilly
LLY
$657B
| $19.4M | 1.42% | 232,500 +2,500 | +1% | +$209K |
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $18M | 1.31% | 376,000 +1,000 | +0.3% | +$47.8K |
|
24
CVS Health
CVS
$92.8B
| $17.2M | 1.26% | 164,000 | – | – |
|
|
ADAP
25
Adaptimmune Therapeutics
ADAP
$15.6M
| $16.6M | 1.21% | +905,000 | New | +$16.6M |
|